miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision ...
Thursday 19 April 2018
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it will be presenting preclinical data on two of its three clinical-stage programs at upcoming scientific conferences. New preclinical data on MRG-110 will be presented at the 2018 Wound Healing Society (WHS) Annual Meeting being held April 25-29, 2018 in Charlotte, NC. MRG-110 is currently in a Phase 1 clinical trial in collaboration with Servier.
In addition, new preclinical data on MRG-201 investigating the anti-fibrotic effects of a microRNA-29 mimic in the eye will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The Company plans to initiate a Phase 2 clinical trial for MRG-201 in cutaneous fibrosis in the second quarter of 2018. miRagen also plans to publicly present preclinical data about microRNA mimics of the miR-183/96/182 cluster and their potential impact on preventing retinal degeneration and preserving photoreceptor function.
The meeting is being held April 29 - May 3, 2018 in Honolulu, HI.
2018 Wound Healing Society Annual Meeting
Oral and Poster Presentation Details
Title: Improved perfusion and wound healing in healthy pigs with MRG-110, an Inhibitor of microRNA-92A
Oral session: Session K: Concurrent Oral Abstracts II
Date: Friday, April 27, 2018, 2:45 p.m. – 2:55 p.m. ET
Location: Room 203B, Charlotte Convention Center
Poster session: WHS Poster Gala & Awards
Poster number: P.IRD4
Date: Friday, April 27, 2018, 7:15 p.m. – 8:45 p.m. ET
Location: Hall C1, Charlotte Convention Center
MRG-110 is an inhibitor of microRNA-92, which has been shown in preclinical studies to be a regulator of new blood vessel creation. miRagen believes microRNA-92 inhibitors may accelerate and improve healing and thus decrease complications of wounds in a variety of settings.
For additional information, please visit the WHS Annual Meeting website: www.woundheal.org
2018 Association for Research in Vision and Ophthalmology Annual Meeting
Oral Presentation Details
Title: Restoring miRNAs of the miR-183/96/182 cluster results in target gene regulation and ameliorates symptoms of retinal degeneration in a mouse model of retinitis pigmentosa
Oral session: Session 473: Signaling in retinal degeneration
Date: Wednesday, May 2, 2018, 3:30 p.m. – 5:15 p.m. HST
Location: Room 315, Hawaii Convention Center
microRNAs of the miR-183/96/182 cluster have been shown to play an important role in the establishment and maintenance of neurosensory cells, including photoreceptors and hair cells (cells associated with hearing). Genetic ablation of the cluster in mice recapitulates features of retinitis pigmentosa in humans, a disease characterized by gradual loss of photoreceptors, resulting in eventual blindness. miRagen has developed mimics corresponding to each of the microRNAs in that cluster and is evaluating how restoring microRNA function could be a therapeutic approach to delaying or even preventing photoreceptor loss.
Poster Presentation Details
Title: Inhibition of ocular fibrosis with a miR-29b mimic
Poster session: Session 489: Retina, drugs
Poster number: C0249
Date: Wednesday, May 2, 2018, 3:30 p.m. – 5:15 p.m. HST
Location: Exhibit Hall, Hawaii Convention Center
MRG-201 is designed to mimic the activity of microRNA-29 and decrease the expression of proteins that are involved in fibrous scar formation. miRagen believes the results from its Phase 1 clinical trial of MRG-201 in induced cutaneous fibrosis, which demonstrated the potential of the product candidate to reduce fibroplasia in humans, may provide support for the therapeutic approach in other pathological fibrotic conditions, including ocular fibrosis.
For additional information, please visit the ARVO Annual Meeting website: www.arvo.org
Never buy or sell based on my posts! My posts are just my opinion!
